

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2017**

Commission File Number: **001-32001**

**Aptose Biosciences Inc.**

(Translation of registrant's name into English)

5955 Airport Road, Suite 228

Mississauga, ON

L4V 1R9

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

On January 5, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated January 5, 2017

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Aptose Biosciences Inc.**  
(Registrant)

Date: January 5, 2017

/s/ Gregory K. Chow  
Gregory K. Chow  
Senior Vice President and Chief Financial Officer

**Aptose Biosciences to Present at Biotech Showcase 2017 Conference**

SAN DIEGO and TORONTO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Biotech Showcase™ 2017 Conference on Tuesday, January 10th at 9:00 a.m. PST in San Francisco, CA.

## Conference Presentation Details:

**Date:** Tuesday, January 10, 2017

**Time:** 9:00 a.m. PST

**Location:** Track 2 - Ballroom Level

Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA 94102

**Webcast:** <https://event.webcasts.com/viewer/event.jsp?ei=1130686>

The audio webcast will be archived shortly after the live event and will be available through the Aptose website at [www.aptose.com](http://www.aptose.com).

**About Aptose Biosciences**

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

Aptose Biosciences  
Greg Chow, CFO  
647-479-9828  
[gchow@aptose.com](mailto:gchow@aptose.com)

SMP Communications  
Susan Pietropaolo  
O: 845-638-6290  
M: 201-923-2049  
[susan@smpcommunications.com](mailto:susan@smpcommunications.com)